Home Business Bharat Biotech's Intranasal Covid booster gets DCGI nod for restricted use

Bharat Biotech’s Intranasal Covid booster gets DCGI nod for restricted use



The Drugs Controller General of India’s (DCGI) has given approval to vaccine manufacturer Bharat Biotech’s Intranasal ‘Five Arms’ Covid 19 booster dose for restricted use.


A source said that the emergency use authorisation (EUA) has been given to the nasal vaccine iNCOVACC for restricted emergency use as the third dose for adults irrespective of having been administered Covaxin or Covishield vaccine doses.


As per the vaccine manufacturer, the nasal route has excellent potential for vaccination due to the organised immune systems of the nasal mucosa. Thus, intranasal immunisation of ChAd-SARS-CoV-2-S can create an immune response in the nose, which is the point of entry for the virus — thereby protecting against disease, infection, and transmission.


The nasal vaccine can be taken after six months of the second dose. As this is non-invasive and needle-free, it becomes easy to administer.


claimed that the intranasal vaccine stimulates a broad immune response. It is likely to block both infection and transmission of COVID-19.


–IANS


avr/shb/

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)



Source link

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Social | Deion Sanders is showing that upward mobility is not just for white coaches

After it was announced that football great Deion Sanders was leaving his coaching job at Jackson State University for an opportunity at the...

Indonesia approves criminal code banning sex outside of marriage

On Tuesday, Indonesia's parliament approved a new criminal code banning sex outside of marriage, which carries a punishment of up to one year...

Recent Comments